Please assess the completion status of the following clinical trial:

Trial Title: DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identifies as a man~* Age 18-35 at enrollment~* Reports having anal sex with a man or trans woman in the past 12 months and one or more of the following criteria in the past 12 months:~  * Any condomless anal sex (not in a mutually monogamous relationship with an HIV-negative partner)~ * Two or more anal sex partners~ * Self-reported STI (gonorrhea, chlamydia, syphilis)~ * Having a known HIV-positive sexual partner~* HIV-negative as determined by a negative 4th generation HIV test at screening and negative rapid 4th generation test at enrollment~* Currently taking PrEP or interested in initiating PrEP~* Eligible to take PrEP~  * Creatinine clearance ≥60 ml/min as estimated by Cockcroft-Gault equation at screening~ * Hepatitis B surface antigen (HBsAg) negative~* Willing and able to provide written informed consent~* Able to read and speak English~* Smartphone ownership compatible with DOT Diary~* Meets local locator requirements~Exclusion Criteria:~* Any reactive HIV test at screening or enrollment~* Signs or symptoms of acute HIV infection at screening or enrollment~* History of pathological bone fracture not related to trauma~* Taking nephrotoxic medications~* History of participation in the active arm of an HIV vaccine trial~* In a mutually monogamous sexual relationship with an HIV-negative partner for the past 12 months~* Does not live, work or play in Atlanta Metropolitan Area, San Francisco, Alameda, Marin, Contra Costa, Santa Clara, or San Mateo Counties~* Unable to commit to study participation for 8 weeks~* Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- DOT Diary Optimization Intervention (Type: EXPERIMENTAL): DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).